https://www.selleckchem.com/pr....oducts/protac-tubuli
roteins and thus single transporter expression systems might lead to over- or underestimation of drug-drug interactions.The introduction of anti-CD20 monoclonal antibodies such as rituximab, ofatumumab, or obinutuzumab improved the therapy of B-cell malignancies even though the precise physiological role and regulation of CD20 remains unclear. Furthermore, CD20 expression is highly variable between different B-cell malignancies, patients with the same malignancy, and even between intraclonal subpopulations in an indivi
Like
Comment
Share
